Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments. Mol Oncol. 2013 Oct; 7(5):968-75.